Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro
Introduction: Although CAR-based immunotherapy is viewed as a promising treatment for tumors, particularly hematological malignancies, solid tumors can pose challenges. It has been suggested that the immunomodulatory medication Lenalidomide (LEN) may increase the effectiveness of CAR T cells in the...
Main Authors: | Mahdi Zarei, Shahriyar Abdoli, Touraj Farazmandfar, Majid Shahbazi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023076685 |
Similar Items
-
Romidepsin Enhances the Killing Ability of NKG2D-CAR-T Cells through Enhanced Expression of NKG2DL against Ovarian Cancer Cells
by: Liang Wang, et al.
Published: (2022-09-01) -
Sodium valproate enhances efficacy of NKG2D CAR-T cells against glioblastoma
by: Junchen Liu, et al.
Published: (2025-01-01) -
CAR-T cells dual-target CD123 and NKG2DLs to eradicate AML cells and selectively target immunosuppressive cells
by: Xin Jin, et al.
Published: (2023-12-01) -
NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
by: Alexandra Frazao, et al.
Published: (2019-03-01) -
Co-expression of IL-21-Enhanced NKG2D CAR-NK cell therapy for lung cancer
by: Yan Zhang, et al.
Published: (2024-01-01)